Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study
Dominique Farge(Hôpital Saint-Louis), Karin Tarte(Inserm), É. Hachulla(Centre Hospitalier Universitaire de Lille), HanChen Wang(McGill Genome Centre), Matthieu Resche‐Rigon(Inserm), Luc Sensebé(Centre National de la Recherche Scientifique), Pauline Lansiaux(Université Paris Cité), G. Pugnet(Hôpital Rangueil), Catney Charles(Université Paris Cité), David Michonneau(Inserm), Nathalie Lambert(Hôpital Necker-Enfants Malades), Christophe Martinaud, David Langlais(McGill University Health Centre), A. Maria(Inserm), Emmanuel Chatelus(Laboratoire National de Référence), Séverine Loisel(Inserm), Inés Colmegna(McGill University Health Centre), Thierry Martin(Western Infirmary), Vissal David Kheav(Assistance Publique – Hôpitaux de Paris), Audrey Cras(Délégation Paris 7)
Cited by 38
Related Papers
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777